| Oral sustained-release tablet -> Monitor Keywords |
|
|
 
Oral sustained-release tabletRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Preparations Characterized By Special Physical Form, Tablets, Lozenges, Or Pills, Sustained Or Differential Release TypeOral sustained-release tablet description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20070092566, Oral sustained-release tablet. Brief Patent Description - Full Patent Description - Patent Application Claims
TECHNICAL FIELD [0001] The present invention relates to oral sustained-release tablets that can maintain constant blood levels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (which is referred to as KRP-197, hereinafter), a candidate compound for the treatment for increased urinary frequency and urinary incontinence. BACKGROUND ART [0002] Urinary incontinence of elderly people has become a public concern and increasing efforts have been devoted to the development of treatment for increased urinary frequency and urinary incontinence. KRP-197, a novel compound developed by Kyorin Pharmaceutical Co., Ltd. (Patent Document 1), is a selective muscarinic antagonist and is considered as a medicinal candidtate compound for the treatment for increased urinary frequency and urinary incontinence (Non-Patent Document 1). An oral solid preparation has already been described as a type of KRP-197 preparation, (Patent Document 2). [0003] Although KRP-197 is rapidly absorbed after an oral administration, the drug has a relatively short half-life and needs to be administered several times a day when given in the form of conventional oral solid preparation. [0004] [Patent Document 1] Japanese Patent Laid-Open Publication No. Hei 7-15943 [0005] [Patent Document 2] WO 01/34147 A1 pamphlet [0006] [Non-Patent Document 1] Bioorg. Med. Chem., 1999, 7, 1151-1161. DISCLOSURE OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION [0007] Urinary frequency and urinary incontinence strip sufferers of freedom of leaving their home for a long time. Thus, a medication that can be taken less frequently not only improves the quality of patients' lives, but also ensures proper use of the drug by decreasing in the chance of patients forgetting to take medication. In addition, muscarinic antagonists are known to cause thirst as the side effect. Therefore, avoiding rapid increases in the blood levels of these compounds should prevent this side effect. The present invention is thus intended to provide an oral sustained-release tablet of KRP-197 that does not cause initial rapid increases in the KRP-197 blood levels and can maintain the constant blood levels. MEANS FOR SOLVING THE PROBLEMS [0008] The preset inventors in their attempt have formulated a pharmaceutical composition containing KRP-197 and a gel-forming material and compressed into tablets. The resulting oral tablets are capable of sustained release of KRP-197. [0009] Accordingly, the present invention concerns the following oral sustained-release tablets: [0010] 1) An oral sustained-release tablet comprising a pharmaceutical composition and a gel-forming material, the pharmaceutical composition containing KRP-197 as an active ingredient; [0011] 2) The oral sustained-release tablet according to 1), wherein the gel-forming material is hydroxypropylmethylcellulose; [0012] 3) The oral sustained-release tablet according to 1), wherein the pharmaceutical composition contains 18 to 73 wt % of hydroxypropylmethylcellulose; [0013] 4) The oral sustained-release tablet according to 1), obtained by mixing KRP-197-containing granulaes with a composition containing a gel-forming material; and [0014] 5) The oral sustained-release tablet according to 4), wherein KRP-197-containing granules are manufactured by using a solution of KRP-197. ADVANTAGE OF THE INVENTION [0015] The oral sustained-release tablets swell as the gel-forming material absorbs water and the resulting gel layer controls the diffusion of the drug from the tablets. BRIEF DESCRIPTION OF THE DRAWINGS [0016] FIG. 1 shows the dissolution curves for Examples 1 through 6 and Comparative Example 1. [0017] FIG. 2 shows KRP-197 blood levels of Example 3 and Comparative Example 1 in dogs Continue reading about Oral sustained-release tablet... Full patent description for Oral sustained-release tablet Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Oral sustained-release tablet patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Oral sustained-release tablet or other areas of interest. ### Previous Patent Application: Gastric retention drug delivery system Next Patent Application: Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Oral sustained-release tablet patent info. IP-related news and info Results in 0.09696 seconds Other interesting Feshpatents.com categories: Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
